Request Demo
Last update 15 Feb 2025
Clevidipine
Last update 15 Feb 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Clevelox, Clevidipine, Clevidipine (USAN/INN) + [5] |
Target |
Mechanism L-type calcium channel blockers(Voltage-gated L-type calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (01 Aug 2008), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC21H23Cl2NO6 |
InChIKeyKPBZROQVTHLCDU-UHFFFAOYSA-N |
CAS Registry167221-71-8 |
Related
60
Clinical Trials associated with ClevidipineNCT06063772
Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia
NCT06402968
Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage
CTR20231630
评估丁酸氯维地平注射用乳剂（QLG2071）对比原研丁酸氯维地平注射用乳剂（Cleviprex®）治疗高血压急症和亚急症的有效性和安全性的多中心、随机、双盲、阳性药物对照、平行设计Ⅲ期研究
[Translation] A multicenter, randomized, double-blind, active drug-controlled, parallel-design phase III study to evaluate the efficacy and safety of clevidipine butyrate injection emulsion (QLG2071) versus the original clevidipine butyrate injection emulsion (Cleviprex®) in the treatment of hypertensive emergencies and sub-urgent conditions
100 Clinical Results associated with Clevidipine
Login to view more data
100 Translational Medicine associated with Clevidipine
Login to view more data
100 Patents (Medical) associated with Clevidipine
Login to view more data
278
Literatures (Medical) associated with Clevidipine01 Apr 2025AMERICAN JOURNAL OF EMERGENCY MEDICINE
Emergency medicine updates: Sympathetic crashing acute pulmonary edema
Review
Author: Brady, William J ; Gottlieb, Michael ; Long, Brit
INTRODUCTION:
Patients with heart failure exacerbation can present in a variety of ways, including sympathetic crashing acute pulmonary edema (SCAPE). Emergency physicians play a key role in the diagnosis and management of this condition.
OBJECTIVE:
This narrative review evaluates key evidence-based updates concerning the diagnosis and management of SCAPE for the emergency clinician.
DISCUSSION:
SCAPE is a subset of acute heart failure, defined as a patient with sudden, severe pulmonary edema and hypertension, resulting respiratory distress, and hypoxemia. This is associated with significantly elevated afterload with fluid maldistribution into the pulmonary system. Evaluation and resuscitation should occur concurrently. Laboratory assessment, electrocardiogram, and imaging should be obtained. Point-of-care ultrasound is a rapid and reliable means of confirming pulmonary edema. Management focuses on respiratory support and vasodilator administration. Noninvasive positive pressure ventilation (NIPPV) with oxygen support is associated with reduced need for intubation, improved survival, and improved respiratory indices. If the patient does not improve or decompensates on NIPPV, endotracheal intubation is recommended. Rapid reduction in afterload is necessary, with the first-line medication including nitroglycerin. High-dose bolus nitroglycerin is safe and effective, followed by an infusion. If hypertension is refractory to NIPPV and high-dose nitroglycerin, other agents may be administered including clevidipine or nicardipine. Angiotensin-converting enzyme inhibitors such as enalaprilat are an option in those with normal renal function and resistant hypertension. Diuretics may be administered in those with evidence of systemic volume overload (e.g., cardiomegaly, peripheral edema, weight gain), but should not be routinely administered in patients with SCAPE in the absence of fluid overload. Caution is recommended in utilizing opioids and beta blockers in those with SCAPE.
CONCLUSION:
An understanding of the current literature concerning SCAPE can assist emergency clinicians and improve the care of these patients.
01 Mar 2025International journal of cardiology. Cardiovascular risk and prevention
Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort
Article
Author: Chilunga, Felix P ; Born, Bert-Jan van der ; van der Linden, Eva ; Galenkamp, Henrike ; Batuo, Hillman ; Moll van Charante, Eric
Background:
Chronic inflammation is a well-recognized contributor to hypertension pathogenesis. However, the role of targeting inflammation in hypertension treatment, particularly through modulation of inflammatory markers like interleukin-6 (IL-6), remains less understood. We investigated the effects of antihypertensive medications with and without IL-6-lowering properties on long-term blood pressure (BP) control in a multi-ethnic cohort in the Netherlands.
Methods:
Participants from HELIUS cohort receiving hypertension treatment were followed over six years. BP control at follow-up was determined using WHO criteria. Due to unavailability of IL-6 data, a literature review was conducted to classify antihypertensives based on their IL-6-lowering properties - a proxy approach. Logistic regression models were used to assess associations between the IL-6-lowering potential of antihypertensives and BP control, both within and between antihypertensive classes. Effect modification by ethnicity was explored.
Results:
A total of 1510 participants were included (mean age 57 years, 62 % women). Within the calcium channel blocker (CCB) class, medications with IL-6-lowering properties (amlodipine and barnidipine) were associated with superior BP control (aOR 1.41, 95 % confidence interval 1.05-1.90) compared to other CCBs (lercanidipine, nifedipine, verapamil, clevidipine, diltiazem). No significant associations were observed within angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors (ACEIs), between different antihypertensive drug classes, nor across ethnic groups.
Conclusion:
Amlodipine and barnidipine were associated with better BP control compared to other CCBs. Our findings provide an important starting point for understanding the role of IL-6 in hypertension management. Further studies are warranted to confirm these observations by directly measuring IL-6 levels and investigating underlying mechanisms.
01 Dec 2024The Annals of pharmacotherapy
Incidence of Hypertriglyceridemia in Patients on Propofol, Clevidipine, or Both
Article
Author: Rowe, A. Shaun ; Black, Rebekah B. ; Fleming, Travis W. ; Brown, Skyler R. ; Johns, Christopher B.
Background::
Propofol and clevidipine (PC) are commonly used in the treatment of critically ill patients. While both medications are lipid emulsions, there is limited evidence concerning the incidence of hypertriglyceridemia (HTG) when these agents are used individually or concurrently.
Objective::
The objective of this study is to determine the effects of propofol, clevidipine, or concurrent PC on triglycerides (TGs) and related outcomes in critically ill adults.
Methods::
This was a retrospective cohort study conducted at an academic medical center. Patients were included if they received ≥24 hours of continuous propofol and/or clevidipine. Excluded were those without TG levels after ≥24 hours of infusion, baseline HTG, acute pancreatitis at admission, or receiving total parenteral nutrition with lipids. The primary outcome was incidence of HTG (defined as a TG level >400 mg/dL). Secondary outcomes included median and peak TG levels, hospital length of stay, intensive care unit length of stay, total lipid infused, time to peak TG level, peak lipase level, and development of pancreatitis.
Results::
In total, 190 patients were studied: 109 in the propofol group, 50 in the clevidipine group, and 31 in the PC group. Incidence of HTG was similar (19 [17.4%] vs 6 [12%] vs 4 [12.9%] patients, P = 0.6246). Peak and median TG levels were similar for propofol, clevidipine, and PC groups (216 mg/dL vs 189.5 mg/dL vs 205 mg/dL, P = 0.7069; 177 mg/dL vs 185.5 mg/dL vs 177 mg/dL, P = 0.6791).
Conclusions and Relevance::
There was a similar incidence of HTG in all groups. The results of this study suggest that the concurrent use of PC should not modify the frequency of TG level monitoring.
100 Deals associated with Clevidipine
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08892 | Clevidipine |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hypertension | NZ | - | 22 Feb 2012 |
| Perioperative hypertension | CH | 11 Jun 2010 | |
| Hypotension | US | 01 Aug 2008 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Dyspnea | Phase 3 | US | 01 Aug 2014 | |
| Heart Failure | Phase 3 | US | 01 Aug 2014 | |
| Acute decompensated heart failure | Phase 3 | US | 01 Dec 2008 | |
| Acute decompensated heart failure | Phase 3 | FR | 01 Dec 2008 | |
| Acute decompensated heart failure | Phase 3 | DE | 01 Dec 2008 | |
| Cerebral Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
| Cerebral Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
| Hemorrhage | Phase 3 | US | 01 Jun 2008 | |
| Hemorrhage | Phase 3 | DE | 01 Jun 2008 | |
| Aneurysm, Intracranial Berry, 1 | Phase 2 | US | 01 Jun 2009 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 12 | (Parenteral Nutrition Energy Dose at 0.6 x Measured REE) | fplyrgcahv(etqtsdhksy) = omqerbcaid oytcsemzjc (dijdfhhbjz, parxhwervl - kftxrqwamn) View more | - | 10 Jun 2022 | ||
(Parenteral Nutrition Energy Dose at 1.0 x Measured REE) | fplyrgcahv(etqtsdhksy) = toervlslkb oytcsemzjc (dijdfhhbjz, amurbjgols - cvtuzvodob) View more | ||||||
Not Applicable | - | lzbfldhhbw(rpbgiynnvk) = ckwbdeqwoi okfydieelm (nognpladck ) | - | 15 May 2022 | |||
Not Applicable | - | wgtccbvczt(dvqdrciiut) = To our knowledge this is the first reported case of severe hypertriglyceridemia and fasting ketoacidosis associated with intravenous CLV. For fasting patients receiving CLV, close monitoring of triglycerides and administration of glucose with insulin should be considered. blpepynebg (fiafihuncn ) | - | 15 Nov 2016 | |||
Phase 2/3 | 50 | jrwyybzrdd(ewaoxhikar) = cfkqlelcuz rtpwixmnfo (ydyutawudg, ikaszlyfir - wdyumfqcmq) View more | - | 18 Feb 2015 | |||
Not Applicable | - | wdolqqfuxl(ddpymsrgsa) = zlokxejfyk hiitmxifxe (kqdnomdkxv ) View more | - | 01 Feb 2015 | |||
wdolqqfuxl(ddpymsrgsa) = nolhnhuirb hiitmxifxe (kqdnomdkxv ) View more | |||||||
Phase 2 | 30 | (Cohort 1: Clevidipine 250 μg (0.5 mL)) | dscwrgyeuz(oupxcurqis) = pykkhbgswh kttndiwgln (icxwmhqmhz, ljhgvllrpb - uvqchmybpz) View more | - | 04 Jun 2014 | ||
(Cohort 2: Clevidipine 500 μg (1.0 mL)) | dscwrgyeuz(oupxcurqis) = dqcpggnoiv kttndiwgln (icxwmhqmhz, hatszbdpqc - hvwtusgwis) View more | ||||||
Phase 4 | 22 | yqqmomscrf(xqolzwucct) = dffaaberxc dedsbpkmel (rhjxewfiuv, klauulqyxa - hctjsjnydj) View more | - | 30 Oct 2013 | |||
Phase 3 | 37 | jhhjsapuis(ipvccrcznr) = kosiumyzqn zgithtteve (zjytjsrnbx, mmlopfehys - irlavwigph) View more | - | 08 Apr 2013 | |||
Phase 3 | 126 | lserwzhmni(zzfletflzz) = nffxruyfok icnyxulyry (hasljmcwle ) | - | 01 Mar 2009 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free